TVGN

Tevogen Bio Holdings Inc

Add to Watchlist

Advanced Chart

0.992

-0.018(-1.780%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

1.0053

Open

0.9984

VWAP

0.98

Vol

283.25K

Mkt Cap

182.46M

Low

0.9717

Amount

278.99K

EV/EBITDA(TTM)

Total Shares

183.89M

186.63M

EV/OCF(TTM)

P/S(TTM)

Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The Company is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, is an off-the-shelf, allogeneic cytotoxic CD8+ T cell therapy designed to fill a critical gap in COVID-19 therapeutic solutions for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of Long COVID. In addition to TVGN 489, it has several product candidates under early-stage development. The Company is developing Epstein-Barr virus (EBV) specific CTLs for potential use in multiple sclerosis (MS) and EBV-associated lymphomas. Its TVGN 601 is being developed for MS, and its TVGN 930 is being developed for EBV-associated lymphomas.

1 Analyst Rating

907.86% Upside

Wall Street analysts forecast TVGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TVGN is 10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

907.86% Upside

Current: 0.992

Low

10.00

Averages

10.00

High

10.00

907.86% Upside

Current: 0.992

Low

10.00

Averages

10.00

High

10.00

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$10

2025-04-21

Reason

D. Boral Capital

Jason Kolbert

Price Target

$10

2025-04-21

Maintains

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$10

2025-03-11

Reason

D. Boral Capital

Jason Kolbert

Price Target

$10

2025-03-11

Maintains

Strong Buy

Reason

D. Boral Capital initiated coverage of Tevogen with a Buy rating and $10 price target. The clinical-stage biotechnology company is developing precision T cell immunotherapies for viral infections, oncology, and neurodegenerative diseases and lead candidate, TVGN-489, is designed to provide targeted immune protection for high-risk COVID-19 patients, the analyst tells investors. The firm believes Tevogen is "positioned to drive innovation in the evolving cell therapy landscape" with a strong intellectual property portfolio and an experienced leadership team, the analyst added.

D. Boral Capital

Jason Kolbert

Strong Buy

Initiates

$10

2025-03-04

Reason

D. Boral Capital

Jason Kolbert

Price Target

$10

2025-03-04

Initiates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Tevogen Bio Holdings Inc (TVGN.O) is -4.31, compared to its 5-year average forward P/E of -0.16. For a more detailed relative valuation and DCF analysis to assess Tevogen Bio Holdings Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-0.16

Current PE

-4.31

Overvalued PE

0.68

Undervalued PE

-1.01

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00